Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 3/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16876690 | 0.97 | RAPGEF4 (0.40) | RAPGEF4DHFRCES2CES1CYP1A2 | |
| SCHEMBL15076828 | 0.79 | LMNA (0.31) | CYP1A2LMNACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL15076835 | 0.79 | — | — | |
| SCHEMBL11714686 | 0.78 | HDAC1 (0.40) | RAPGEF4CYP1A2LMNACYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL28644880 | 0.76 | KDM1A (0.39) | CYP1A2LMNACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL392345 | 0.75 | RAPGEF4 (0.56) | RAPGEF4DHFRCES2CES1CA1 | |
| SCHEMBL2075947 | 0.73 | CA12 (0.45) | RAPGEF4CES2CES1CYP1A2LMNA | |
| SCHEMBL17588980 | 0.72 | TRPV4 (0.52) | LMNATDP1 | |
| Hydrochloric Acid SCHEMBL16876683 | 0.72 | DHODH (0.35) | TDP1 | |
| SCHEMBL5801110 | 0.72 | TUBB1 (0.36) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12344586-B2 | Process for the preparation of biphenylamines | ADAMA MAKHTESHIM LTD. (IL) | 2025-07-01 | — | — | US | disclosed |
| EP-4423069-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | ECCOGENE INC. (US) | 2024-07-16 | — | — | US | disclosed |
| CN-118176183-A | HIF-2 alpha inhibitors and methods of use thereof | 艾库斯生物科学有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-118084679-A | Synthesis method of 3',4',5 '-trifluoro- [1,1' -biphenyl ] -2-amine | 天津均凯农业科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117430516-A | Industrial method for synthesizing fluxapyroxad benzidine intermediate by one-pot method | 江苏中旗科技股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117285427-A | Preparation method of fluxapyroxad intermediate 3',4',5' -trifluoro biphenyl-2-amine | 山东京博农化科技股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344586-B2 | Process for the preparation of biphenylamines | DDT, AGPS, PAH | RAPGEF4 1780/4885DHFR 744/4885CES2 3608/4885 |
| US-12037339-B2 | Substituted imidazoles as GLP-1 receptor agonists | GLP1R, GIPR, SLC5A1 | RAPGEF4 2162/4885DHFR 3569/4885CES2 4091/4885 |
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | RAPGEF4 4573/4885DHFR 145/4885CES2 804/4885 |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | RAPGEF4 2343/4885DHFR 542/4885CES2 4037/4885 |
| US-12071411-B2 | Inhibitors of HIF-2α and methods of use thereof | HIF1AN, HIF1A, EGLN2 | RAPGEF4 2145/4885DHFR 1005/4885CES2 2136/4885 |
| US-20230159466-A1 | INHIBITORS OF HIF-2ALPHA AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | RAPGEF4 2093/4885DHFR 1369/4885CES2 2563/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | RAPGEF4 2343/4885DHFR 542/4885CES2 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.